What Changed, and What Didnt In late 2023, the FDA moved 19 widely used peptides to its Category 2 list, effectively banning compounding pharmacies from preparing them
search "BPC-157 systematic review" on PubMed) ACS Labs and WuXi AppTec analytical testing roundups on COA discrepancy rates in research-use-only peptide vendors PeptideLaws and Lumalex Law, trade coverage of Peptide Sciences voluntary shutdown, March 6, 2026 Orrick and Polsinelli law firm client alerts on FDA PCAC scheduling for BPC-157, TB-500, epitalon, and related peptides, 2026
Both lines must appear together for full reimbursement on every injection claim you submit
Waldman, Scott A
Always follow good laboratory practices, including disinfecting vial stoppers, using sterile syringes and needles, and operating within controlled environments such as laminar flow hoods
Chronic Insomnia Double-Blind Trial The double-blind matched-pairs study by Schneider-Helmert (1988) evaluated DSIP at 25 nmol/kg IV administered on three consecutive afternoons in 16 chronic insomniac patients